Dataset Information

Is C-peptide a predictor of severity of coronary artery disease in metabolic syndrome? An observational study.

ABSTRACT:

Background

Various cardiovascular disease (CVD) risk factors have been implicated to correlate with the severity of the disease. Present study was conducted to correlate one such risk factor i.e. fasting serum C-peptide with the presence or absence and the severity of CVD in Indian population.

Methods

68 patients with metabolic syndrome who underwent coronary angiogram for suspected CVD were included. Their fasting serum C-peptide levels were measured in addition to routine biochemical and cardiological tests. They were divided into 2 groups - those with a positive coronary angiography findings (Group 1) and those with normal coronary angiograms (Group 2). The former group was further divided into those with an Acute Coronary Syndrome (ACS) (Group 1a) and those with Chronic Stable Angina (CSA) (Group 1b). SYNTAX scoring was done to assess the severity of coronary artery disease in groups 1a and 1b. Levels of C-peptide were compared between the groups.

Results

The mean C-peptide of all patients was 1.9 (±0.8) ng/mL. Among the group 2 patients, mean serum C-peptide value was 1.6 (±0.4) ng/mL. And it was 2.7 (±0.8) ng/mL and 1.7 (±0.9) ng/mL among the ACS and the CSA groups respectively. The ACS and CSA group had statistically significant higher values of C-peptide compared to patients with normal coronary angiograms. The two-way ANOVA done to find out the variability of C-peptide among the 3 groups revealed significant differences among the groups with a p-value of <0.001. When correlated with SYNTAX scores, this yielded significant results.

Conclusion

C-peptide levels appear to correlate with the severity of the CVD as measured by SYNTAX score.

SUBMITTER: Harnishsingh B

PROVIDER: S-EPMC6309290 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Is C-peptide a predictor of severity of coronary artery disease in metabolic syndrome? An observational study.

Harnishsingh Bhatia B Rama Bhat B

Indian heart journal 20180719

<h4>Background</h4>Various cardiovascular disease (CVD) risk factors have been implicated to correlate with the severity of the disease. Present study was conducted to correlate one such risk factor i.e. fasting serum C-peptide with the presence or absence and the severity of CVD in Indian population.<h4>Methods</h4>68 patients with metabolic syndrome who underwent coronary angiogram for suspected CVD were included. Their fasting serum C-peptide levels were measured in addition to routine bioche ...[more]

PMID: 30595240

Similar Datasets

Project description:IntroductionIndividuals with metabolic syndrome (MetS) are at increasing risk of coronary artery disease (CAD). We investigated the common metabolic perturbations of CAD and MetS via serum metabolomics to provide insight into potential associations.MethodsNon-targeted serum metabolomics analyses were performed using ultra high-performance liquid chromatography coupled with Q Exactive hybrid quadrupole-orbitrap high-resolution accurate mass spectrometry (UHPLC-Q-Orbitrap HRMS) in samples from 492 participants (272 CAD vs. 121 healthy controls (HCs) as cohort 1, 55 MetS vs. 44 HCs as cohort 2). Cross-sectional data were obtained when the participants were recruited from the First Affiliated Hospital of Zhengzhou University. Multivariate statistics and Student's t test were applied to obtain the significant metabolites [with variable importance in the projection (VIP) values >1.0 and p values <0.05] for CAD and MetS. Logistic regression was performed to investigate the association of identified metabolites with clinical cardiac risk factors, and the association of significant metabolic perturbations between CAD and MetS was visualized by Cytoscape software 3.6.1. Finally, the receiver operating characteristic (ROC) analysis was evaluated for the risk prediction values of common changed metabolites.ResultsThirty metabolites were identified for CAD, mainly including amino acids, lipid, fatty acids, pseudouridine, niacinamide; 26 metabolites were identified for MetS, mainly including amino acids, lipid, fatty acids, steroid hormone, and paraxanthine. The logistic regression results showed that all of the 30 metabolites for CAD, and 15 metabolites for MetS remained significant after adjustments of clinical risk factors. In the common metabolic signature association analysis between CAD and MetS, 11 serum metabolites were significant and common to CAD and MetS outcomes. Out of this, nine followed similar trends while two had differing directionalities. The nine common metabolites exhibiting same change trend improved risk prediction for CAD (86.4%) and MetS (90.9%) using the ROC analysis.ConclusionSerum metabolomics analysis might provide a new insight into the potential mechanisms underlying the common metabolic perturbations of CAD and MetS.

Project description:Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels. HCR is increasingly used to treat multivessel coronary artery disease that includes stenoses in the proximal left anterior descending artery and at least 1 other vessel, but its effectiveness has not been rigorously evaluated.This National Institutes of Health-funded, multicenter, observational study was conducted to explore the characteristics and outcomes of patients undergoing clinically indicated HCR and multivessel PCI for hybrid-eligible coronary artery disease, to inform the design of a confirmatory comparative effectiveness trial.Over 18 months, 200 HCR and 98 multivessel PCI patients were enrolled at 11 sites. The primary outcome was major adverse cardiac and cerebrovascular events (MACCE) (i.e., death, stroke, myocardial infarction, repeat revascularization) within 12 months post-intervention. Cox proportional hazards models were used to model time to first MACCE event. Propensity scores were used to balance the groups.Mean age was 64.2 ± 11.5 years, 25.5% of patients were female, 38.6% were diabetic, and 4.7% had previous stroke. Thirty-eight percent had 3-vessel coronary artery disease, and the mean SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score was 19.7 ± 9.6. Adjusted for baseline risk, MACCE rates were similar between groups within 12 months post-intervention (hazard ratio [HR]: 1.063; p = 0.80) and during a median 17.6 months of follow-up (HR: 0.868; p = 0.53).These observational data from this first multicenter study of HCR suggest that there is no significant difference in MACCE rates over 12 months between patients treated with multivessel PCI or HCR, an emerging modality. A randomized trial with long-term outcomes is needed to definitively compare the effectiveness of these 2 revascularization strategies. (Hybrid Revascularization Observational Study; NCT01121263).

Dataset Information

Is C-peptide a predictor of severity of coronary artery disease in metabolic syndrome? An observational study.

Background

Methods

Results

Conclusion

Publications

Is C-peptide a predictor of severity of coronary artery disease in metabolic syndrome? An observational study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure